PPARA and metabolic dysfunction-associated steatohepatitis: Clearly, PPAR modulation represents a promising target in NASH, given the relative success of PPAR-γ effects noted from the PIVENS trial and other longitudinal datasets,18 with the suggestion that pan-PPAR agonism is likely to demonstrate true clinical benefit across all major accepted primary and secondary endpoints.